How to buy BioAtla (BCAB.US) stock |

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioAtla stock

Own BioAtla stock in just a few minutes.

San Diego-based BioAtla, a company that produces cancer therapies, wrapped its initial public offering.

How to buy shares in BioAtla

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioAtla. Find the stock by name or ticker symbol: BCAB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioAtla reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioAtla, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioAtla. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioAtla share price

Use our graph to track the performance of BCAB stocks over time.

BioAtla shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$27.15 - USD$76.63
50-day moving average USD$56.0729
200-day moving average USD$48.5243
Wall St. target priceUSD$76.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy BioAtla shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioAtla stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioAtla financials

Revenue TTM USD$429,000
Gross profit TTM USD$-19,504,000
Return on assets TTM -14.8%
Return on equity TTM -46.57%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.5 billion

TTM: trailing 12 months

Shorting BioAtla shares

There are currently 2.1 million BioAtla shares held short by investors – that's known as BioAtla's "short interest". This figure is 54.1% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting BioAtla shares can be evaluated.

BioAtla's "short interest ratio" (SIR)

BioAtla's "short interest ratio" (SIR) is the quantity of BioAtla shares currently shorted divided by the average quantity of BioAtla shares traded daily (recently around 395158.06451613). BioAtla's SIR currently stands at 5.27. In other words for every 100,000 BioAtla shares traded daily on the market, roughly 5270 shares are currently held short.

To gain some more context, you can compare BioAtla's short interest ratio against those of similar companies.

However BioAtla's short interest can also be evaluated against the total number of BioAtla shares, or, against the total number of tradable BioAtla shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioAtla's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 BioAtla shares in existence, roughly 60 shares are currently held short) or 0.0685% of the tradable shares (for every 100,000 tradable BioAtla shares, roughly 69 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioAtla.

Find out more about how you can short BioAtla stock.

BioAtla share dividends

We're not expecting BioAtla to pay a dividend over the next 12 months.

BioAtla overview

BioAtla, Inc. , a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site